March 27 (Reuters) - Swiss pharma company Novartis said on Friday it will acquire California-based biotech company Excellergy in a deal worth up to $2 billion. Under the agreement, Novartis said it would pay up to $2 billion in upfront and milestone payments. The transaction is expected to close in the second half of 2026, subject to customary conditions, including...

– Acquisition brings together Excellergy's differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of Novartis, with a total potential transaction value of up to $2 billion – – Exl-111 is a potentially first-in-class allergic trifunctional ECRI targeting the IgE axis and is currently in Phase 1 development – PALO ALTO, Calif., March 27, 2026 (GLOBE NEWSWIRE)...

BEIJING, March 27 (Reuters) - Four Chinese universities, including two linked to the People's Liberation Army, bought Super Micro Computer ( SMCI ) servers with restricted AI chips over the past year, procurement data shows, even as the U.S. clamps down on sales of some advanced processors to China. It was not clear how the servers were sourced. Concerned about...

March 27 (Reuters) - The British competition regulator on Friday said it is investigating five companies including, Autotrader and Just Eat, as part of its crackdown on fake reviews and misleading star ratings. ...